New treatment approach for triple negative breast cancer using targeted siRNA delivery
Official title: In Situ Albumin Binding siRNAs for Triple Negative Breast Cancer Tumor Penetration and Molecularly Targeted Therapy
Funded at Vanderbilt University · NIH-10925327 · Data updated 2026-11-12
This study is testing a new way to deliver a special treatment directly to tumors in patients with triple negative breast cancer, making it easier for the medicine to reach the cancer and potentially improve how well it works.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Vanderbilt University NIH-funded |
| Lab location | 1 site (Nashville, UNITED STATES) |
| Project start | July 5, 2021 |
| Project end | June 30, 2026 |
| Funding year | 2024 |
| Award (this year) | $522,993 |
| NIH project number | 5R01CA260958-04 |
| Project ID | NIH-10925327 on NIH RePORTER |
Who could benefit from this research
✓Could help
Ideal candidates for this research are patients diagnosed with triple negative breast cancer who may benefit from innovative therapeutic approaches.
✕Less likely to help
Patients with other types of breast cancer or those who do not have access to the specific treatment protocols may not benefit from this research.
What this research studies
This research focuses on developing a novel method to deliver small interfering RNA (siRNA) specifically to tumors in patients with triple negative breast cancer. By modifying siRNA molecules to enhance their ability to penetrate tumor tissues, the study aims to overcome existing barriers that limit the effectiveness of RNA-based therapies. The approach involves using a special chemical modification that allows siRNA to bind to albumin in the bloodstream, which helps it reach the tumor more effectively. This could lead to more effective treatments for patients with hard-to-target cancer drivers.
Why it matters
Potential benefit: If successful, this research could provide a more effective treatment option for patients with triple negative breast cancer, potentially improving their outcomes.
How similar studies have gone: Previous research has shown promise in using similar siRNA delivery methods, indicating potential for success in this novel approach.
Where this research is happening
-
Vanderbilt University
Nashville, United States Active
Researchers
- Principal investigator: Duvall, Craig Lewis — Vanderbilt University
- Study coordinator: Duvall, Craig Lewis
Related research
Other NIH-funded projects on the same topics.
-
PET scans to track glutamine use in triple-negative breast cancer
This project uses special PET scans with an amino-acid tracer to see how triple-negative breast cancers use glutamine so doctors can better match metabolism-targeted treatments to patients.
-
Improving Targeted Therapy for Triple Negative Breast Cancer
This project aims to develop a new way to deliver targeted medicines directly to triple-negative breast cancer tumors using special RNA molecules.
-
Using PET imaging to understand glutamine metabolism in triple-negative breast cancer
This study is looking at how a substance called glutamine affects triple-negative breast cancer to find better ways to treat it, using special imaging to see how much glutamine is in the cancer cells and helping doctors choose the best therapies for patients.
-
Targeted therapy for triple-negative breast cancer using antibody-drug conjugates
This study is working on new treatments for triple-negative breast cancer that aim to target cancer cells directly while being kinder to healthy cells, so patients can have better outcomes with fewer side effects.
-
Targeted therapy for aggressive breast cancer
This study is testing a new treatment for triple-negative breast cancer that uses tiny particles to deliver medicine directly to cancer cells, helping to stop them from spreading and improving how well the treatment works.
-
Using nanotechnology to target therapy for triple negative breast cancer
This study is exploring new ways to treat triple negative breast cancer using tiny particles to deliver special molecules that can help stop cancer cells from growing, aiming to create better treatment options that work specifically for this type of cancer and have fewer side effects.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.